Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.

Freeman J, Baglino S, Friborg J, Kraft Z, Gray T, Hill M, McPhee F, Hillson J, Lopez-Talavera JC, Wind-Rotolo M.

J Viral Hepat. 2014 Jun;21(6):e1-9. doi: 10.1111/jvh.12243.

PMID:
24827902
2.

Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid JF, Klein F, Stamatatos L.

J Virol. 2012 Dec;86(23):12676-85. doi: 10.1128/JVI.01893-12. Epub 2012 Sep 12.

3.

Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ.

PLoS One. 2012;7(7):e41832. doi: 10.1371/journal.pone.0041832. Epub 2012 Jul 25. Erratum in: PLoS One. 2012;7(10). doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458. Stamatatos, Leonidis [corrected to Stamatatos, Leonidas].

4.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.

Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC.

J Exp Med. 2012 Jul 30;209(8):1469-79. doi: 10.1084/jem.20120423. Epub 2012 Jul 23.

5.

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.

J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.

6.

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L.

J Virol. 2011 Jul;85(14):7095-107. doi: 10.1128/JVI.00411-11. Epub 2011 May 4.

7.

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, Barnett S, Stamatatos L, Haigwood NL.

J Virol. 2011 Jun;85(11):5262-74. doi: 10.1128/JVI.02419-10. Epub 2011 Mar 23.

8.

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, Strong RK, Stamatatos L, Schief WR.

Structure. 2010 Sep 8;18(9):1116-26. doi: 10.1016/j.str.2010.06.010.

9.

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.

Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L.

J Virol. 2010 Apr;84(7):3443-53. doi: 10.1128/JVI.02617-09. Epub 2010 Jan 27.

10.

Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, Reinherz EL, Stamatatos L, Strong RK.

J Virol. 2010 Jan;84(2):1076-88. doi: 10.1128/JVI.02113-09. Epub 2009 Nov 11.

11.

Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Polacino P, Larsen K, Galmin L, Suschak J, Kraft Z, Stamatatos L, Anderson D, Barnett SW, Pal R, Bost K, Bandivdekar AH, Miller CJ, Hu SL.

J Med Primatol. 2008 Dec;37 Suppl 2:13-23. doi: 10.1111/j.1600-0684.2008.00325.x.

12.

Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Kraft Z, Strouss K, Sutton WF, Cleveland B, Tso FY, Polacino P, Overbaugh J, Hu SL, Stamatatos L.

J Virol. 2008 Jun;82(12):5912-21. doi: 10.1128/JVI.00389-08. Epub 2008 Apr 9.

13.

Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Derby NR, Gray S, Wayner E, Campogan D, Vlahogiannis G, Kraft Z, Barnett SW, Srivastava IK, Stamatatos L.

Virology. 2007 Sep 30;366(2):433-45. Epub 2007 Jun 8.

14.

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L.

J Virol. 2007 Jun;81(12):6402-11. Epub 2007 Mar 28.

15.

Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein.

Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, Stamatatos L.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):1022-30.

PMID:
17067273
16.

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I, Vojtech L, Zhu T, Srivastava IK, Barnett SW, Stamatatos L.

Virology. 2006 Nov 25;355(2):138-51. Epub 2006 Aug 22.

17.
18.

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.

Xu R, Srivastava IK, Kuller L, Zarkikh I, Kraft Z, Fagrouch Z, Letvin NL, Heeney JL, Barnett SW, Stamatatos L.

Virology. 2006 Jun 5;349(2):276-89. Epub 2006 Mar 9.

19.

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L.

J Virol. 2005 Jul;79(14):9069-80.

20.

Effect of antimetabolites on antigen Vi synthesis and variability in S. typhi.

KOZINSKI AW, KRAFT Z, OPARA Z.

Nature. 1957 Jan 26;179(4552):201. No abstract available.

PMID:
13400137

Supplemental Content

Support Center